• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Natera’s (NTRA) Kupando MRD Deal a Stepping Stone in Its Oncology Strategy?

    Simply Wall St·08/26/2026 13:23:38
    语音播报
    • Natera, Inc. recently announced a collaboration with Kupando Therapeutics in which its Latitude tissue-free MRD assay will monitor circulating tumor DNA dynamics in a Phase 1 trial of Kupando's lead immunotherapy KUP-101 for advanced skin cancers, with serial testing across multiple timepoints at oncology centers including those in Germany.
    • This collaboration highlights how Natera’s Latitude platform can be applied as a tissue-agnostic tool for real-time treatment response assessment across diverse solid tumors in early-stage drug development.
    • We’ll now examine how integrating Latitude into Kupando’s Phase 1 KUP-101 trial could influence Natera’s investment narrative around oncology-focused MRD testing.

    Outshine the giants: these 18 early-stage AI stocks could fund your retirement.

    Natera Investment Narrative Recap

    To own Natera, you need to believe its cell free DNA technology can translate into broad, clinically adopted tests across oncology, women’s health, and organ health, while the company manages its still sizable losses and high spending. The Kupando collaboration reinforces the oncology MRD story but does not materially change the near term focus on expanding Signatera and Latitude usage or the key risk of regulatory and reimbursement setbacks.

    Among recent announcements, the June PMDA approval of Signatera for colorectal cancer in Japan looks most relevant. Like the Kupando trial, it underscores Natera’s effort to embed its MRD platforms into standard oncology practice, but here with immediate commercial implications: a new reimbursable market that could support revenue growth even as R&D and commercial expenses remain elevated.

    Yet, while these developments are encouraging, investors should also be aware that...

    Read the full narrative on Natera (it's free!)

    Natera's narrative projects $4.2 billion revenue and $300.7 million earnings by 2029.

    Uncover how Natera's forecasts yield a $282.14 fair value, a 16% downside to its current price.

    Exploring Other Perspectives

    NTRA 1-Year Stock Price Chart
    NTRA 1-Year Stock Price Chart

    Some of the lowest ranked analysts saw revenue rising only about 16.8% annually and not reaching profitability by 2029, which contrasts sharply with the Kupando MRD collaboration and raises useful questions about how tighter regulation could shape very different outcomes for Natera over time.

    Explore 4 other fair value estimates on Natera - why the stock might be worth 16% less than the current price!

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Natera research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
    • Our free Natera research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Natera's overall financial health at a glance.

    Want Some Alternatives?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.